Less scans, less stress? study tests smarter sarcoma surveillance
NCT ID NCT04751409
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether having fewer follow-up scans after surgery for soft tissue sarcoma can lower patients' fear of cancer coming back. About 227 adults who finished treatment will be split into two groups: one gets limited follow-up, the other gets intense follow-up. Researchers will track anxiety and other patient-reported outcomes over two years to see which approach is better for mental well-being.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If this trial succeeds, it could show that less frequent follow-up scans reduce anxiety without missing cancer recurrence, potentially improving quality of life for sarcoma survivors.
- What could go wrong
- This is a small, early-phase study (227 people) that only measures patient-reported anxiety, not cancer outcomes. Results may not apply to all patients or change standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II SOFT TISSUE SARCOMA OF THE TRUNK AND EXTREMITIES AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could 5 days of radiation replace 25 for sarcoma patients?
- Experimental combo aims to boost immune attack on sarcoma before surgery
- New drug combo aims to stall rare Cancer's spread
- Can fewer, stronger radiation doses before sarcoma surgery reduce wound problems?
- New hope for rare sarcomas: chemo plus immunotherapy combo enters phase III trial
- New hope for sarcoma patients: drug combo aims to shrink tumors